Navigation Links
Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
Date:11/14/2011

TORONTO, Nov. 14, 2011 /PRNewswire/ -- Modern Mobility Aids, Inc. (MDRM.OB) (the "Company"), headquartered in Nevada, USA, has completed its due diligence on the acquisition of all the common stock of Lumigene Technologies, Inc. ("Lumigene") and expects to close on the transaction by November 30, 2011.

LumiGene is a Canadian molecular diagnostics company developing point-of-care healthcare products for quick and effective pathogen and disease detection.  The acquisition of Lumigene will allow the Company to address the increasing demand from healthcare professionals worldwide for more rapid and cost-efficient DNA testing, especially for point-of-care products enabling immediate diagnosis.  Current testing methods take days to perform by specially-trained technical personnel in an offsite laboratory environment. There is a large need to speed up the DNA sample preparation, amplification and detection at the sample collection site to obtain immediate and accurate results.

Mohamed K. Karatella, President and CEO, elaborated on the portable and easy-to-use products being developed for commercialization by Lumigene: "Staff at hospitals, health clinics and even airports need fast detection of pathogens, infectious diseases and other ailments right at the point of DNA sampling.  Delivering the first available solution to produce such reliable results within an hour with Lumigene's automated and economic technology will open up a broad range of applications and global market potential.  We are very pleased to welcome the talented technical team at Lumigene to add to our management strength and bring further innovative bioscience technologies to our Company."

A significant portion of the purchase price for Lumigene will be paid based on the achievement of key business and technology milestones, including patent application filing, development of a "Beta Cartridge" and successful completion of external Beta testing of Lumigene's POSiChek™ System within the deadlines agreed to by the Company.  This acquisition of Lumigene will help the Company expedite its healthcare innovation strategy.

About Modern Mobility Aids, Inc.

Modern Mobility Aids, Inc. was first incorporated under the laws of the State of Nevada on December 19, 2007, under the name of Glider Inc. Its business plan was to sell and distribute products for mobility-challenged individuals. The Company changed its name to Modern Mobility Aids, Inc. on April 22, 2010 with initial plans to distribute products for mobility-challenged individuals. In May of 2011, the business focus of the Company evolved with a rapid expansion strategy in the life sciences and healthcare industry.  A mandate was created to acquire companies within the biopharma sector, targeting both innovative research and development as well as scalable manufacturing capacity in three niche market segments: CRAM (Contract Research and Manufacturing for Life Sciences Companies), HEALTHCARE INNOVATION (Novel Drug and Device Delivery Format Packaging) and BIOPHARMA PARTNERSHIPS (Strategic Development and Production Alliances).

CONTACT INFO:
Modern Mobility Aids, Inc.
Public Relations and Shareholder Information:
416 901 8831 investor@mdrmgroup.com


'/>"/>
SOURCE Modern Mobility Aids, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Modern Plastics Announces ISO 13485:2003 Certification for Medical Industry
2. Modern Plastics Announces Full Operation of Its New Facility in Shelton, Conn.
3. LasikPlusĀ® Research Reveals Excellent Results From Modern LASIK
4. Modern Plastics SUSTARINĀ® C (Acetal) Product Uses Special Manufacturing Technology to Ensure Every Sheet and Rod Are Free of Centerline or Core Porosity
5. Advance could change modern electronics
6. Global Food Security Depends on Modern Agriculture
7. DuPont Leader: Drought-Tolerant Crops Developed Through Modern Breeding are Key to Sustainably Increasing Grain Production
8. New research reveals the ancestral populations of India and their relationships to modern groups
9. MIT: Alarming use of energy in modern manufacturing methods
10. DNA 11 Unveils Modern-Day Family Portraits at The Museum of Science and Industry's Smart Home: Green + WIRED Exhibit
11. The Modern DeBakey VAD™ To Be Introduced For the First Time in the U.S. : HeartAssist 5™ Pediatric VAD Features Industry Exclusive Direct Blood Flow Measurement System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017 Symic Bio, a biopharmaceutical company ... category of therapeutics, announced today the completion of enrollment ... artery disease. The trial will evaluate the safety and ... the reduction of restenosis following angioplasty. ... for SB-030," said Nathan Bachtell , M.D., Chief ...
(Date:2/24/2017)... Blood Corporation (NYSE: CO ) ("CCBC" or ... laboratory testing, hematopoietic stem cell processing and stem cell ... the third quarter and first nine months of fiscal ... Quarter of Fiscal 2017 Highlights Revenues ... 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... 23, 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ... biopharmaceutical company in China, today announced its financial results for ... Fourth Quarter 2016 Financial Highlights ... 21.7% in RMB terms, or increased by 13.6% in USD ... quarter of 2015. Gross profit increased by ...
(Date:2/24/2017)... 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), ... a Key Opinion Leader event to highlight new clinical ... poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium ... will be held in-person and via live webcast on ... AM PST at the Lotte New York Palace Hotel ...
Breaking Biology Technology:
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... by 2021 from $8.3 billion in 2016 at a ... to 2021. Report Includes - An overview of ... market trends, with data from 2015 and 2016, and ... - Segmentation of the market on the basis of ...
(Date:2/3/2017)... SAN ANTONIO , Feb. 3, 2017  Texas Biomedical ... Dr. Larry Schlesinger as the Institute,s ... of Texas Biomed effective May 31, 2017. He is currently ... and Director of the Center for Microbial Interface Biology at ... Dr. Schlesinger as the new President and CEO of Texas ...
(Date:2/1/2017)... 2017 IDTechEx Research, a leading provider of ... the availability of a new report, Sensors for Robotics: Technologies, ... Reading ... ... Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: ...
Breaking Biology News(10 mins):